Adrestia Therapeutics
Latest round
- Series A
Last raised
- Dec 2020
Total raised
- $9.2M
Investors
- 2
About Adrestia Therapeutics
Based in Cambridge, UK, and founded in 2017, Adrestia Therapeutics Ltd, a spin-out of the University of Cambridge in the UK, operates as a drug development company that develops treatments for genetic diseases. The company was co-founded by its CSO, Steve Jackson, Gabi Balmus, and Yaron Galanty. In June 2023, Insmed, Inc. acquired Adrestia Therapeutics Ltd. Adrestia Therapeutics offers a synthetic rescue drug development platform, which is a drug development platform that develops synthetic rescue therapies for genetic diseases. The firm’s synthetic rescue platform uses high-throughput techniques like whole genome assays to analyze vast amounts of genetic data. Through this analysis, the platform identifies genes functionally linked to the disease-causing mutation.
Who invested in Adrestia Therapeutics
2 investors across 1 round
See all investors in Adrestia Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Dec 11, 2020
Amount
$9.2M
Investors
Questions about Adrestia Therapeutics
Who invested in Adrestia Therapeutics?
Adrestia Therapeutics has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Adrestia Therapeutics raised?
Adrestia Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Adrestia Therapeutics last raise money?
Adrestia Therapeutics's most recent round on record is a Series A, in Dec 2020.
What does Adrestia Therapeutics do?
Based in Cambridge, UK, and founded in 2017, Adrestia Therapeutics Ltd, a spin-out of the University of Cambridge in the UK, operates as a drug development company that develops treatments for genetic diseases.
Where is Adrestia Therapeutics headquartered?
Adrestia Therapeutics is headquartered in Cambridge, UK.
Which VCs invest in companies like Adrestia Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Adrestia Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Adrestia Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.